FDA Watchers: Gottlieb May Fly Under Trump Deregulatory Radar With Product-Specific Moves

August 24, 2017 at 2:57 PM
In the wake of President Donald Trump's push toward deregulation, one regulatory policy watcher tells Inside Health Policy that the Scott Gottlieb-led FDA may be implementing a new regulatory paradigm centered more on individual regulatory decisions as opposed to formal rulemaking -- highlighting the agency's newly announced tobacco plan as one example. But another regulatory attorney called the move toward less guidance development inefficient and wasteful. Bruce Levinson, senior vice president of regulatory intervention at the Center for Regulatory...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.